Expression of NDRG2 in esophageal squamous cell carcinoma

Hai Shi1, Nanlin Li, Shujun Li

  • 1State Key Laboratory of Cancer Biology, Department of Gastrointestinal Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.

Cancer Science
|March 25, 2010
PubMed

Insights

N-Myc downstream-regulated gene 2 (NDRG2) is downregulated in esophageal squamous cell carcinoma (ESCC). Lower NDRG2 expression correlates with poor prognosis and increased proliferation, while higher NDRG2 levels indicate better survival in ESCC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • N-Myc downstream-regulated gene 2 (NDRG2) is a differentially expressed gene implicated in various cancers.
  • Its role in esophageal squamous cell carcinoma (ESCC) remains to be fully elucidated.

Purpose of the Study:

  • To investigate the expression patterns of NDRG2 in ESCC tissues.
  • To analyze the correlation between NDRG2 expression and clinicopathological features, prognosis, and cellular behavior in ESCC.

Main Methods:

  • Immunohistochemistry was employed to assess NDRG2 and C-MYC expression in 154 ESCC samples and normal tissues.
  • Statistical analyses including Wilcoxon-Mann-Whitney test, Kaplan-Meier survival analysis, and Cox regression were performed.
  • NDRG2 was overexpressed in ESCC cell lines (EC9706, EC109) via plasmid transfection for in vitro and in vivo functional studies.

Main Results:

  • NDRG2 expression was significantly lower in ESCC tissues compared to normal tissues, with C-MYC showing an inverse trend.
  • Reduced NDRG2 expression correlated with advanced T stage, TNM stage, and poor differentiation in ESCC.
  • High NDRG2 expression was associated with longer survival, and low NDRG2, pT1 stage, and pM1 were independent poor prognostic factors.

Conclusions:

  • NDRG2 plays a crucial role in regulating ESCC cell proliferation and apoptosis.
  • NDRG2 expression levels are closely linked to the prognosis of esophageal squamous cell carcinoma.
  • NDRG2 represents a potential therapeutic target and prognostic biomarker for ESCC.

Related Concept Videos

Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
Esophagus01:24

Esophagus

The esophagus, a muscular conduit linking the pharynx and stomach, measures roughly 10 inches (25.4 cm) and sits behind the trachea. It remains collapsed when not swallowing. The esophagus follows a predominantly straight path through the thoracic mediastinum and enters the abdominal cavity through a diaphragmatic opening known as the esophageal hiatus.
The movement of edibles from the pharynx into the esophagus is facilitated by the upper esophageal sphincter, which is formed primarily by the...
Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more similar...